Section Arrow
IMA.NASDAQ
- ImageneBio Inc
Quotes are at least 15-min delayed:2025/07/30 05:31 EDT
Pre Market
Last
 --
-- (--)
Bid
6.08
Ask
15.22
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 15.2
-1.17 (-7.15%)
Day High 
16 
Prev. Close
16.37 
1-M High
18 
Volume 
25.47K 
Bid
6.08
Ask
15.22
Day Low
15.2 
Open
16 
1-M Low
14.4 
Market Cap 
59.90M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 15.95 
20-SMA 16.08 
50-SMA 15.69 
52-W High 18 
52-W Low 0.9707 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.68/-0.95
Enterprise Value
63.64M
Balance Sheet
Book Value Per Share
2.77
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.46
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNFATNF Pharmaceuticals Inc.0.1544+0.0294+23.52%-- 
Pre Market 0.1398 -0.0146 -9.46%
NCNANuCana plc0.0503-0.0047-8.55%-- 
Pre Market 0.0475 -0.0028 -5.57%
CLDICalidi Biotherapeutics0.6317+0.0821+14.94%-- 
Pre Market 0.5651 -0.0666 -10.54%
SLRXSalarius Pharmaceuticals Inc.0.9996+0.2585+34.88%-- 
Pre Market 0.9193 -0.0803 -8.03%
SRPTSarepta Therapeutics15.83+1.97+14.21%15.76PE
Pre Market 17.38 +1.55 +9.79%
Quotes are at least 15-min delayed:2025/07/30 05:31 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncologyproduct candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.